Patents by Inventor Magali A. Zundel

Magali A. Zundel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII Molecules with Reduced VWF Binding
    Publication number: 20170020992
    Abstract: The present invention relates to a recombinant Factor VIII molecule, wherein said molecule has reduced vWF binding capacity, and wherein said molecule is covalently conjugated with at least one side group.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Gert Bolt, Bernd Peschke, Mikael Kofod-Hansen, Jens Buchardt, Henning Ralf Stennicke, Henrik Oestergaard, Marianne Kjalke, Eva H. Norling Olsen, Jens Jacob Hansen, Magali Zundel
  • TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES
    Publication number: 20160355859
    Abstract: Methods for conjugating peptides are provided comprising i) reacting a peptide with a first compound comprising a functional group in the presence of a transglutaminase capable of incorporating said compound into the peptide to form a transaminated peptide, and ii) reacting said transaminated peptide with e.g. a functionalized polymer capable of reacting with the functional group incorporated in the peptide in the enzymatic reaction.
    Type: Application
    Filed: June 16, 2016
    Publication date: December 8, 2016
    Inventors: NILS LANGELAND JOHANSEN, MAGALI ZUNDEL, FLORENCIO ZARAGOZA DORWALD
  • Targeted Delivery of Factor VIII Proteins to Platelets
    Publication number: 20160251409
    Abstract: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 1, 2016
    Inventors: Henrik Oestergaard, Anthony Pusateri, Thomas R. Barnett, Jens Buchardt, Bernd Peschke, Mikael Kofod-Hansen, Magali A. Zundel, Carsten Behrens, Eva H. Norling Olsen, Henning Stennicke
  • Conjugated FVIII variants
    Patent number: 9018166
    Abstract: The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.
    Type: Grant
    Filed: February 7, 2011
    Date of Patent: April 28, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Carsten Behrens, Jens Buchardt, Magali Zundel
  • USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST
    Publication number: 20140274903
    Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.
    Type: Application
    Filed: April 29, 2014
    Publication date: September 18, 2014
    Applicant: NOVO NORDISK HEALTHCARE AG
    Inventors: Carsten Behrens, Patrick W. Garibay, Magali Zundel, Niels Kristian Klausen, Soeren Bjoern
  • COUPLING OF POLYPEPTIDES AT THE C-TERMINUS
    Publication number: 20140045753
    Abstract: The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.
    Type: Application
    Filed: October 15, 2013
    Publication date: February 13, 2014
    Applicant: NOVO NORDISK HEALTH CARE AG
    Inventors: Bernd Peschke, Magali Zundel
  • CONJUGATED FVIII VARIANTS
    Publication number: 20120322738
    Abstract: The present invention relates to conjugated Factor VIII variants. The present invention in particular relates to conjugated FVIII variants comprising different polymeric groups as well as use thereof.
    Type: Application
    Filed: February 7, 2011
    Publication date: December 20, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Carsten Behrens, Jens Buchardt, Magali Zundel
  • TARGETED DELIVERY OF FACTOR VIII PROTEINS TO PLATELETS
    Publication number: 20120093840
    Abstract: The invention described herein relates to novel molecules and polypeptides comprising at least one amino acid sequence having significant identity with (homology to) human Factor VIII or biologically active portion(s) thereof, related molecules (such as nucleic acids encoding such polypeptides), compositions (such as pharmaceutical formulations) comprising such polypeptides, and methods of making and using such polypeptides.
    Type: Application
    Filed: April 6, 2010
    Publication date: April 19, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Henrik Østergaard, Anthony Pusateri, Thomas R. Barnett, Jens Buchardt, Bernd Peschke, Mikael Kofod-Hansen, Magali A. Zundel, Carsten Behrens, Eva H. Norling Olsen, Henning Stennicke
  • Modification of Factor VIII
    Publication number: 20110306551
    Abstract: A Factor VIII derivative of formula (I): wherein: B represents C2 to C10 alkylene; m represents 0 or an integer from 1 to 19, n represents an integer from 1 to 20, and the sum of m and n is from 1 to 20; P represents a mono or polyradical of Factor VIII obtained by removing m+n carbamoyl groups from the side chains of glutamine residues in Factor VIII; and M represents a moiety (M1) that increases the plasma half-life of the Factor VIII derivative or a reporter moiety (M2); or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 18, 2010
    Publication date: December 15, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Magali Zundel, Bernd Peschke, Ditte Maria Karpf, Kjeld Madsen
  • Use of Galactose Oxidase for Selective Chemical Conjugation of Protractor Molecules to Proteins of Therapeutic Interest
    Publication number: 20100028939
    Abstract: This invention relates to novel compounds, methods for selective chemical conjugation of protractor molecules and the use thereof for diagnostic and/or therapeutic purposes.
    Type: Application
    Filed: April 1, 2008
    Publication date: February 4, 2010
    Applicant: Novo Nordisk Healthcare A/G
    Inventors: Carsten Behrens, Patrick William Garibay, Magali Zundel, Niels Kristian Klausen, Soren E. Bjorn
  • Modulating Enzymatic Processes by Addition of Diolcontaining Substances
    Publication number: 20100009917
    Abstract: The present invention relates to a method for increasing the selectivity of an enzyme, which method comprises performing the reaction in the presence of an enhancing compound selected from one of ethylene glycol, propylene glycol or glycerol.
    Type: Application
    Filed: February 20, 2008
    Publication date: January 14, 2010
    Applicant: Novo Nordisk Health Care AG
    Inventors: Jens Buchardt, Nils Langeland Johansen, Magali Zundel
  • Transglutaminase Mediated Conjugation of Peptides
    Publication number: 20090264366
    Abstract: Methods for conjugating peptides are provided comprising i) reacting a peptide with a first compound comprising a functional group in the presence of a transglutaminase capable of incorporating said compound into the peptide to form a transaminated peptide, and ii) reacting said transaminated peptide with e.g. a functionalized polymer capable of reacting with the functional group incorporated in the peptide in the enzymatic reaction.
    Type: Application
    Filed: June 30, 2009
    Publication date: October 22, 2009
    Applicant: Novo Nordisk Healthcare AG
    Inventors: Nils Langeland Johansen, Magali Zundel, Florencio Zaragoza Dorwald
  • Conjugation of Peptides
    Publication number: 20090253166
    Abstract: Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.
    Type: Application
    Filed: March 18, 2009
    Publication date: October 8, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Magali A. Zundel, Bernd Peschke, Florencio Zaragoza Dorwald, Niels Peter Fiil, Nils Langeland Johansen, Henning Ralf Stennicke
  • Selectively conjugated peptides and methods of making the same
    Patent number: 7524813
    Abstract: Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: April 28, 2009
    Assignee: Novo Nordisk Health Care AG
    Inventors: Magali A. Zundel, Bernd Peschke, Florencio Zaragoza Dörwald, Niels Peter Fiil, Nils Langeland Johansen, Henning Ralf Stennicke
  • C-Terminally Pegylated Growth Hormones
    Publication number: 20090105134
    Abstract: Conjugated growth hormones of the structure (I) are provided together with methods for manufacturing said conjugates. The conjugates are useful in therapy.
    Type: Application
    Filed: February 10, 2006
    Publication date: April 23, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Magali Zundel, Bernd Peschke
  • Coupling of Polypeptides at the C-Terminus
    Publication number: 20090082254
    Abstract: The present invention relates to novel polypeptides, methods for their synthesis, pharmaceutical compositions comprising the novel polypeptides as well as their use in medicaments for therapeutic applications.
    Type: Application
    Filed: February 13, 2007
    Publication date: March 26, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Bernd Peschke, Magali Zundel
  • NOVEL GLP-1 ANALOGUES LINKED TO ALBUMIN-LIKE AGENTS
    Publication number: 20090005312
    Abstract: Novel GLP-1 agonists which are protracted by coupling to a protraction protein.
    Type: Application
    Filed: August 6, 2008
    Publication date: January 1, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Thomas Kruse Hansen, Magali Zundel, Kjeld Madsen, Anne Svendsen, Christine Bruun Schiodt, Jesper Lau
  • GLP-2 compounds, formulations, and uses thereof
    Patent number: 7411039
    Abstract: The present invention relates to novel human glucagon-like peptide-2 (GLP-2) peptides and human glucagon-like peptide-2 derivatives which have a protracted profile of action as well as polynucleotide constructs encoding such peptides, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.
    Type: Grant
    Filed: October 14, 2003
    Date of Patent: August 12, 2008
    Assignee: Novo Nordisk A/S
    Inventors: Lars Thim, Susanne Bang, Niels Christian Kaarsholm, Anette Sams Nielsen, Nils Langeland Johansen, Kjeld Madsen, Magali Zundel, Peter Thygesen, Birgitte Michelsen
  • Modified Proteins
    Publication number: 20080108557
    Abstract: A method of conjugating peptides and proteins by means of glycosyltransferase is provided.
    Type: Application
    Filed: September 29, 2005
    Publication date: May 8, 2008
    Applicant: Novo Nordisk HealthCare A/G
    Inventors: Carsten Behrens, Patrick William Garibay, Magali Zundel
  • Conjugation of peptides
    Publication number: 20070111926
    Abstract: Methods for the selective conjugation of peptides which comprises an enzymatic incorporation of a functional group at the C-terminal end of a peptide followed by reaction with a second compound comprising the moiety to be conjugated to the peptide, wherein said second compound comprises a functional group which selectively reacts with the incorporated functional group.
    Type: Application
    Filed: March 31, 2006
    Publication date: May 17, 2007
    Applicant: Novo Nordisk A/S
    Inventors: Magali Zundel, Bernd Peschke, Florencio Dorwald, Niels Fiil, Nils Johansen, Henning Stennicke